U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C16H28O7
Molecular Weight 332.3893
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ROSIRIDIN

SMILES

CC(C)=CC[C@H](O)C(\C)=C\CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=PBPYEEMQIFDGSQ-MOIFMYGASA-N
InChI=1S/C16H28O7/c1-9(2)4-5-11(18)10(3)6-7-22-16-15(21)14(20)13(19)12(8-17)23-16/h4,6,11-21H,5,7-8H2,1-3H3/b10-6+/t11-,12+,13+,14-,15+,16+/m0/s1

HIDE SMILES / InChI

Molecular Formula C16H28O7
Molecular Weight 332.3893
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 6 / 6
E/Z Centers 1
Optical Activity UNSPECIFIED

Description

The genus Rhodiola (Crassulaceae) consists of nearly 200 species and among them Rhodiola rosea L. is the best known. The plant is indigenous to the arctic regions of eastern Siberia, but it is also found in the northern parts of Europe and Alaska. Similar to Siberian ginseng, the root of R. rosea is traditionally used as a tonic in Russia, and as an antidepressant and anti inflammatory drug. Rosiridin, a monoterpene, has mainly stimulant properties and elicits the greatest monoamine inhibitory effect. Rosiridin is noted as specifically inhibiting MAO-B to a significant extent (over 80%), and shows potential beneficial effect in depression and senile dementia.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
5.38 null [pIC50]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown

PubMed

Sample Use Guides

In Vivo Use Guide
in rats: Eight rats were treated with Rhodiola rosea roots and rhizomes(28 mg/kg p.o.) containing rosavins (5.5%), salidroside (1.4%), rosin (0.8%), and rosiridin (5%).
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Record UNII
71AL4K0H19
Record Status Validated (UNII)
Record Version